Harvard Bioscience (HBIO) Revenue (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Revenue data on file, last reported at $20.8 million in Q1 2026.

• Revenue for Q1 2026 came in at $20.8 million, down 4.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $85.5 million (down 6.42% YoY), and the FY2025 annual result was $86.6 million, down 8.06% from the prior year.
• Revenue fell to $20.8 million in Q1 2026 per HBIO's latest filing, from $23.7 million in the prior quarter.
• Over five years, Revenue peaked at $30.0 million in Q1 2023 and troughed at $20.4 million in Q2 2025.
• A 5-year average of $25.1 million and a median of $24.6 million in 2024 frame the typical range for Revenue.
• The sharpest annual moves came in 2022 and 2024: Revenue increased 6.63% in 2022, then dropped 19.69% in 2024.
• A 5-year view of Revenue shows it stood at $28.4 million in 2022, then declined by 0.96% to $28.2 million in 2023, then decreased by 12.78% to $24.6 million in 2024, then decreased by 3.34% to $23.7 million in 2025, then dropped by 12.56% to $20.8 million in 2026.
• Business Quant data shows HBIO's Revenue at $20.8 million in Q1 2026, $23.7 million in Q4 2025, and $20.6 million in Q3 2025.